Zhonghua bing li xue za zhi = Chinese journal of pathology
Guidelines on tests of PIK3CA mutation in breast cancer in China (2025 version)
Abstract
随着乳腺癌精准治疗的发展及相关循证医学证据的不断积累，PIK3CA基因突变检测在乳腺癌诊断与治疗中的规范化需求日益明显。本共识基于国内外新近文献及循证医学原则，围绕PIK3CA基因突变检测的关键问题展开全面阐述，重点涵盖检测流程优化、常见与罕见突变位点解析、质控要求以及多位点突变的临床意义等内容。旨在提升检测的准确性与可重复性，为乳腺癌患者的个体化治疗策略提供重要依据。.
Source and rights
Published by Zhonghua bing li xue za zhi = Chinese journal of pathology, 2025. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
More in oncology
- Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyNational Comprehensive Cancer Network · 2026
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance) [2] · 2026
